NASDAQ:ORGS Orgenesis - ORGS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.31 -0.06 (-4.38%) (As of 03/28/2023 04:17 PM ET) Add Compare Share Share Today's Range$1.30▼$1.3950-Day Range$1.24▼$2.5952-Week Range$1.13▼$4.04Volume40,136 shsAverage Volume76,189 shsMarket Capitalization$36.01 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Orgenesis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside358.0% Upside$6.00 Price TargetShort InterestHealthy1.30% of Float Sold ShortDividend StrengthN/ASustainability-1.49Upright™ Environmental ScoreNews Sentiment0.49Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector380th out of 1,002 stocksPharmaceutical Preparations Industry169th out of 488 stocks 3.5 Analyst's Opinion Consensus RatingOrgenesis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Orgenesis has a forecasted upside of 358.0% from its current price of $1.31.Amount of Analyst CoverageOrgenesis has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.30% of the float of Orgenesis has been sold short.Short Interest Ratio / Days to CoverOrgenesis has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Orgenesis has recently decreased by 19.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrgenesis does not currently pay a dividend.Dividend GrowthOrgenesis does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOrgenesis has received a 66.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Gene therapy medication", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Orgenesis is -1.49. Previous Next 1.9 News and Social Media Coverage News SentimentOrgenesis has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Orgenesis this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orgenesis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.69% of the stock of Orgenesis is held by insiders.Percentage Held by InstitutionsOnly 16.81% of the stock of Orgenesis is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Orgenesis is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orgenesis is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrgenesis has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Orgenesis (NASDAQ:ORGS) StockOrgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.Read More Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGS Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comOrgenesis' (ORGS) Buy Rating Reaffirmed at BenchmarkMarch 24, 2023 | finance.yahoo.comOrgenesis Inc. (NASDAQ:ORGS) Q4 2022 Earnings Call TranscriptMarch 28, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. March 23, 2023 | benzinga.comOrgenesis Stock (NASDAQ:ORGS), Guidance and ForecastMarch 21, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022March 21, 2023 | finance.yahoo.comOrgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022March 17, 2023 | finance.yahoo.comOrgenesis Schedules Fourth Quarter 2022 Business Update Conference CallMarch 16, 2023 | finance.yahoo.comOrgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across CaliforniaMarch 28, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. February 27, 2023 | finance.yahoo.comOrgenesis Inc. Announces Closing of $3.7 Million Registered Direct OfferingFebruary 23, 2023 | finance.yahoo.comOrgenesis Inc. Announces Pricing of $3.7 Million Registered Direct OfferingJanuary 4, 2023 | finance.yahoo.comInvestors in Orgenesis (NASDAQ:ORGS) have unfortunately lost 73% over the last five yearsDecember 22, 2022 | msn.comOrgenesis's Return On Capital Employed InsightsDecember 20, 2022 | finance.yahoo.comOrgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma ModelNovember 23, 2022 | 247wallst.comNew Dimensions Trading Discloses Large Position in ORGS / OrgenesisNovember 16, 2022 | finance.yahoo.comOrgenesis Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 13, 2022 | seekingalpha.comOrgenesis (ORGS) Q3 2022 Earnings Call TranscriptNovember 12, 2022 | finance.yahoo.comLoss-Making Orgenesis Inc. (NASDAQ:ORGS) Expected To Breakeven In The Medium-TermNovember 11, 2022 | finanznachrichten.deOrgenesis Inc.: Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022November 10, 2022 | finance.yahoo.comOrgenesis Schedules Third Quarter 2022 Business Update Conference CallNovember 10, 2022 | finance.yahoo.comOrgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022November 7, 2022 | msn.comEXCLUSIVE: Orgenesis' Subsidiary Secures $50M Investment To Accelerate Point-of-Care Services GrowthNovember 7, 2022 | finance.yahoo.comOrgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care ServicesOctober 28, 2022 | finance.yahoo.comOracle Helps Healthcare Organizations Create Patient-Centered Supply ChainsSeptember 19, 2022 | reuters.comORGS.OQ - Orgenesis Inc | Stock Price & Latest News | ReutersSeptember 10, 2022 | nasdaq.comShareholders in Orgenesis (NASDAQ:ORGS) are in the red if they invested five years agoAugust 16, 2022 | seekingalpha.comOrgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGS Company Calendar Last Earnings11/04/2021Today3/28/2023Next Earnings (Estimated)5/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees111Year Founded2008Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+338.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,890,000.00 Net Margins-33.80% Pretax Margin-33.20% Return on Equity-38.65% Return on Assets-17.21% Debt Debt-to-Equity Ratio0.46 Current Ratio2.91 Quick Ratio2.90 Sales & Book Value Annual Sales$36.03 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book1.20Miscellaneous Outstanding Shares27,490,000Free Float25,379,000Market Cap$37.66 million OptionableNot Optionable Beta0.89 Social Links Key ExecutivesVered CaplanChairman, President & Chief Executive OfficerNeil ReithingerChief Financial Officer, Secretary & TreasurerSarah FerberChief Scientific OfficerHeiko von der LeyenMedical DirectorEfrat Assa-KunikChief Development OfficerKey CompetitorsVistaGen TherapeuticsNASDAQ:VTGNEledon PharmaceuticalsNASDAQ:ELDNYumanity TherapeuticsNASDAQ:YMTXPalatin TechnologiesNYSE:PTNCheckpoint TherapeuticsNASDAQ:CKPTView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 7,198 shares on 2/13/2023Ownership: 0.809%Dimensional Fund Advisors LPBought 12,000 shares on 2/9/2023Ownership: 0.143%Simplex Trading LLCSold 500 shares on 2/2/2023Ownership: 0.000%Chapin Davis Inc.Bought 20,000 shares on 1/30/2023Ownership: 0.078%View All Institutional Transactions ORGS Stock - Frequently Asked Questions Should I buy or sell Orgenesis stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orgenesis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORGS shares. View ORGS analyst ratings or view top-rated stocks. What is Orgenesis' stock price forecast for 2023? 1 brokerages have issued twelve-month price objectives for Orgenesis' stock. Their ORGS share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 338.0% from the stock's current price. View analysts price targets for ORGS or view top-rated stocks among Wall Street analysts. How have ORGS shares performed in 2023? Orgenesis' stock was trading at $1.95 at the beginning of the year. Since then, ORGS shares have decreased by 29.7% and is now trading at $1.37. View the best growth stocks for 2023 here. Are investors shorting Orgenesis? Orgenesis saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 304,800 shares, a decrease of 19.1% from the February 28th total of 376,800 shares. Based on an average daily trading volume, of 70,300 shares, the days-to-cover ratio is currently 4.3 days. Approximately 1.3% of the shares of the stock are short sold. View Orgenesis' Short Interest. When is Orgenesis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023. View our ORGS earnings forecast. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) issued its earnings results on Thursday, November, 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.39. The company earned $7.61 million during the quarter. Orgenesis had a negative net margin of 33.80% and a negative trailing twelve-month return on equity of 38.65%. What is Orgenesis' stock symbol? Orgenesis trades on the NASDAQ under the ticker symbol "ORGS." Who are Orgenesis' major shareholders? Orgenesis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.81%), Dimensional Fund Advisors LP (0.14%), Chapin Davis Inc. (0.08%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Orgenesis' stock price today? One share of ORGS stock can currently be purchased for approximately $1.37. How much money does Orgenesis make? Orgenesis (NASDAQ:ORGS) has a market capitalization of $37.66 million and generates $36.03 million in revenue each year. The company earns $-14,890,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. How many employees does Orgenesis have? The company employs 111 workers across the globe. Does Orgenesis have any subsidiaries? The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.Read More How can I contact Orgenesis? Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for the company is www.orgenesis.com. The company can be reached via phone at (480) 659-6404 or via email at orgs@crescendo-ir.com. This page (NASDAQ:ORGS) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.